2601, 2022
Monthly focus on regulatory status of new targeted therapies in oncology- December 2021
CHMP December 16 - lorlatinib - NSCLC ALK fusions: EMA's [...]
2112, 2021
Shooting Cancer – Highlights Monthly focus on regulatory status of new targeted therapies in oncology – November 2021
CHMP 11 November- Sotorasib-NSCLC KRAS G12C: The EMA's Committee for [...]
911, 2021
NTRK inhibitors, a successful example of a tissue-agnostic approach in anticancer targeted therapy
In the last three years, two TRK inhibitors, larotrectinib and [...]
2209, 2021
KRAS, a new weapon for the fight against lung cancer and more
Between May and June 2021, two KRAS G12C inhibitors received [...]
3006, 2021
Lung cancer: molecular markers and new opportunities to treat the early and advanced disease
In May, the European Commission extended the use of atezolizumab [...]
3105, 2021
Utility and use of NGS in clinical oncology: ESMO recommendations for patients with metastatic cancers
Last summer, the European Society of Medical Oncology (ESMO) published [...]
204, 2021
Europe approves the first anti-PD-L1/L1 therapy for patients with MSI-H/dMMR colorectal cancer
On January 26, 2021, the European Medicines Agency approved pembrolizumab [...]
103, 2021
A breakthrough for the targeted therapy of RET+ tumours with new selective inhibitors
Last year the Food and Drug Administration approved two selective [...]